Bacteriophages, the viruses that prey on bacteria, have long been touted as precision weapons against antibiotic-resistant pathogens. By locking onto specific receptors on the bacterial surface, they can in principle single out harmful strains within the teeming community of the gut while leaving benign neighbors untouched. Yet phage therapy outcomes in the intestine have been strikingly inconsistent: sometimes bacterial loads collapse, sometimes resistant mutants emerge, and sometimes nothing measurable happens at all. A new study published in iScience by Anouk Bertola, Nicolas Wenner, Leonardo Lemos Rocha, Timothy G. Keys, and Médéric Diard of the University of Basel offers a quantitative explanation for this unpredictability, showing that the resident microbiota itself constrains phage success by capping the population size of susceptible bacteria.
The research team focused on the concept of a phage replication threshold, the minimum density of susceptible host cells required for a lytic phage population to sustain itself. Below this density, the rate at which new phage particles are produced through infection and lysis falls short of the rate at which virions are lost through clearance, diffusion barriers, and failed encounters with hosts. Although this threshold concept was established decades ago in simplified liquid cultures, its value in the complex, spatially structured, and immunologically active environment of the intestinal tract had never been rigorously quantified. Because the density of any invading bacterial species in the gut depends heavily on the composition of the resident microbiota, the researchers hypothesized that increasing microbial complexity should suppress phage replication and, in turn, alter the selection for phage resistance.
To test this hypothesis, the team assembled an elegant experimental system built around two clinically relevant, multidrug-resistant Escherichia coli strains. The first, designated EcST73, was isolated from a healthy traveler and belongs to sequence type ST73; the second, EcST1193, came from a case of neonatal sepsis. Each strain produces a distinct polysaccharide capsule, or K-antigen, which serves as the receptor for a specific lytic phage: φYodit, a Kayfunavirus that binds the K5 capsule of EcST73, and φMoritz, a Vectrevirus that binds the K1 capsule of EcST1193. Both phages belong to the order Autographivirales and possess short, non-contractile tails. The choice of capsule-targeting phages carried a practical advantage: phage-resistant mutants that shed their capsules form visibly translucent colonies on salt-free agar plates, allowing the researchers to track the rise and fall of resistance directly from fecal samples without any genetic engineering of the target population.
The experimental backbone consisted of three mouse lines harboring microbiotas of increasing complexity. Antibiotic-treated mice, whose colonization resistance had been destroyed by ampicillin, permitted the E. coli strains to reach enormous densities, averaging around 1010 colony-forming units per gram of feces. Gnotobiotic mice carrying a low-complexity microbiota of only a few species supported intermediate colonization levels in the range of 106 to 107 CFU per gram. Conventional specific-pathogen-free mice, with their full complement of resident microbes, mounted strong colonization resistance and kept the invading strains at or below roughly 105 CFU per gram, with EcST1193 in fact being cleared from most animals entirely. Bacterial populations stabilized about 48 hours after oral infection, so the researchers administered a single oral dose of 109 plaque-forming units of the matching phage at precisely that time point.
The results were unambiguous. In antibiotic-treated and low-complexity microbiota mice, phage titers rose and remained detectable for several days, evidence of active replication. In conventional mice, by contrast, phages became undetectable within 48 hours in most animals, indicating that the small E. coli population could not sustain viral reproduction. Strikingly, the phages had no significant effect on total E. coli loads in any of the models. Where replication did occur, resistance followed rapidly. In antibiotic-treated animals, capsule-defective mutants appeared within a day of phage administration and soon dominated the population, after which phage titers declined as susceptible hosts vanished. Sequencing of these resistant clones revealed mutations in genes governing capsule synthesis, transport, and regulation, including emrR, a transcriptional regulator of capsule production, kpsM, required for capsule polysaccharide transport, and, in EcST1193, the neuS and neuE genes involved in polysialic acid biosynthesis for the K1 capsule. Many clones also carried mutations in maltose metabolism genes, a signature of E. coli adaptation to the antibiotic-treated gut.
When the researchers plotted phage titers against bacterial densities across all animals, a clear threshold emerged. Phage replication and the consequent selection for capsule-defective mutants occurred only when susceptible bacteria exceeded approximately 106 CFU per gram of feces, equivalent to roughly 1.3 × 106 bacteria per milliliter of cecal content. Below this line, no resistant mutants were ever observed, because phages simply could not replicate and therefore exerted no selective pressure. Notably, this in vivo threshold is about a hundred times higher than the proliferation threshold of 104 bacteria per milliliter previously determined in vitro for phage T4 and E. coli. The authors attribute this discrepancy to the harsh realities of the intestinal environment: viscous contents impede phage diffusion, structural heterogeneity creates microenvironments where susceptible cells hide, off-target adsorption diverts virions, intestinal flow washes particles away, epithelial cells uptake phages, and digestive enzymes and bile salts inactivate them. Furthermore, fecal counts may overestimate the fraction of cells that are actively growing and expressing the phage receptor, since capsule production is often heterogeneously expressed in Enterobacteriaceae.
Perhaps the most consequential finding came from a competition experiment designed to expose a hidden subpopulation of susceptible cells. The researchers co-infected antibiotic-treated mice with a one-to-one mixture of wild-type EcST73 and a phage-resistant capsule-knockout mutant, each tagged with a distinct antibiotic-resistance marker so the two could be quantified separately. Without phage, the two strains coexisted stably. With phage φYodit, the wild-type population crashed by several orders of magnitude but then stabilized at around 2.4 × 106 CFU per gram, remarkably close to the replication threshold. The phage went extinct in six of ten animals, and after viral extinction the susceptible population rebounded in some mice. Crucially, mini-plaque assays confirmed that most surviving wild-type cells remained fully phage-susceptible even after ten days of coexistence with the virus. In other words, the microbiota is not the only force that can shelter susceptible bacteria; a dense population of resistant cells is sufficient on its own to dilute phage spread below the critical threshold.
This observation carries sobering implications for phage therapy. The researchers showed that flooding the gut with phages at concentrations hundreds of times higher than the susceptible population, roughly 2 × 109 virions against 5 × 106 bacteria per gram of feces, still failed to eliminate the targets. Passive therapy, in which an overwhelming excess of phages drives host extinction without secondary rounds of replication, is therefore unlikely to achieve complete decolonization of the intestine. Instead, phages reduce susceptible populations to a residual level just beneath the replication threshold, where they persist indefinitely and can regrow once phages disappear. The characteristics of this refuge population and the niche it occupies remain open questions, but its existence helps explain why phage cocktails in previous mouse and calf studies reduced, yet never eradicated, intestinal loads of E. coli and Klebsiella pneumoniae.
For clinical translation, the threshold offers a practical decision rule. Human intestinal loads of E. coli vary between 102 and 109 CFU per gram of feces, so phages should not be expected to replicate, or to select for resistance, in patients carrying fewer than 106 bacteria per gram. Conversely, patients whose microbiotas have been disturbed by antibiotics or pathogen-driven dysbiosis often harbor densities well above the threshold, making them plausible candidates for successful phage treatment. Even a transient reduction in bacterial load may suffice to improve outcomes and reduce mortality, as multiple animal studies have demonstrated. The authors acknowledge limitations: only two phage-bacterium pairs and a single phage dose were tested, and both phages were capsule-specific Autographivirales whose properties might influence the threshold value. Nevertheless, comparable effects have been reported with diverse phages using other receptors, suggesting that the microbiota-constrained replication threshold may be a general feature of phage-bacteria interactions in the gut, one that must be respected if phage therapy is to fulfill its promise as a precision tool for microbiota engineering.
Subject of Research: Phage replication threshold in the mammalian gut and its dependence on microbiota-constrained bacterial density
Article Title: Microbiota-constrained bacterial density limits phage infection in the gut and allows persistence of susceptible cells
Article References: Bertola, A., Wenner, N., Rocha, L. L., Keys, T. G., & Diard, M. (2026). Microbiota-constrained bacterial density limits phage infection in the gut and allows persistence of susceptible cells. iScience, 29(11), Article 117433. https://doi.org/10.1016/j.isci.2026.117433
Image Credits: AI Generated
DOI: 10.1016/j.isci.2026.117433
Keywords: bacteriophage, phage therapy, gut microbiota, Escherichia coli, replication threshold, phage resistance, capsule, colonization resistance, antibiotic-resistant bacteria, Enterobacteriaceae, mouse model, microbiota engineering
News Source: Morgan Morrow. (October 7, 2026). Gut Microbiota Sets a Density Threshold That Decides Whether Phages Can Infect. Scienmag.
